Injectable Manufacturing

Manufacturing of Cytotoxic and Non-Cytotoxic Drugs in a Multiproduct Facility

Available from Baxter BioPharma Solutions

Manufacturing of Cytotoxic and Non-Cytotoxic Drugs in a Multiproduct Facility

Content Summary

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical. Outsourcing of drug product manufacturing to a contract manufacturing organization with experience in handling different products in multiproduct facilities can be an option. However, the experience and expertise of the CMO is crucial to avoid the risk of cross-contamination of the drug product, as failures or weaknesses in this process can pose risk to the end-user.

Access this content

Choose an option below

Your content has been opened.

Please verify you are a human before downloading this content.

Please verify you are a human before adding this content to your library.


Register to access this content


Verify your email to access this content

Code sent. Enter it in the modal

Your content has been opened.

Please verify you are a human before opening this content.

Why do I need to verify I’m human?

Please verify you are a human before opening this content.

Your content has been opened.

Please verify you are a human before downloading this content.

Please verify you are a human before opening this content.

The content will open in a new window. You may need to allow popups for this site.